Opus Genetics, Inc. (IRD)
IRD moved a median of -0.20% 30 minutes after news, and -0.49% by the close. How IRD actually reacts to news — the realized, point-in-time move the market made, measured across 183 labeled events over the last three years with zero look-ahead.
IRD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.19% | 54% | 183 |
| 30-min | -0.20% | 46% | 183 |
| 60-min | -0.49% | 43% | 183 |
| to close | -0.49% | 46% | 182 |
| Middle 50% of IRD reactions | -1.65% to +1.08% |
|---|---|
| Median reaction (30-min) | -0.20% |
| Measured reactions | 183 |
Half of all Opus Genetics, Inc. news events land between -1.65% and +1.08% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IRD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.45% | 55% | +1.24% |
| Coverage initiations | 47 | -0.22% | 47% | -0.30% |
| Rating reiterations | 38 | +0.26% | 50% | -0.89% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how IRD ranks against every other measured name →
That’s how IRD usually reacts — get an email when it moves on news →Email me when IRD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IRD's baseline. Nothing else.
Recent IRD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Press release | GlobeNewswire | -1.66% | -2.04% | |
| Form 8-K Opus Genetics, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -2.91% | -6.80% | |
| Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 | Press release | GlobeNewswire | -2.91% | -6.80% | |
| Opus Genetics to Present at the Chardan Annual Healthcare Conference | Press release | GlobeNewswire | -0.75% | -9.01% | |
| Form 8-K Opus Genetics, Inc. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +4.50% | -1.95% | |
| Form 8-K Opus Genetics, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +16.35% | +7.71% | |
| Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 | Press release | GlobeNewswire | +16.35% | +7.71% | |
| Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences | Press release | GlobeNewswire | +2.59% | +15.29% | |
| Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.00% | +2.74% | |
| Form EFFECT Opus Genetics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.08% | +1.39% | |
| Form S-3 Opus Genetics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -1.88% | |
| Form 10-Q Opus Genetics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.88% | |
| Form 8-K Opus Genetics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | -2.36% | |
| Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update | Press release | GlobeNewswire | +0.53% | -2.36% | |
| Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease | Press release | GlobeNewswire | -2.29% | -2.15% | |
| Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results | Press release | GlobeNewswire | +1.33% | -2.43% | |
| Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease | Press release | GlobeNewswire | +1.68% | -4.01% | |
| Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes | Press release | GlobeNewswire | +2.42% | +7.53% | |
| Form EFFECT Opus Genetics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.64% | +4.64% | |
| Form 8-K Opus Genetics, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | +1.83% | |
| Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases | Press release | GlobeNewswire | +0.64% | +4.64% | |
| Form S-3 Opus Genetics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.10% | -1.95% | |
| Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts | Press release | GlobeNewswire | -1.46% | -3.15% | |
| Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.66% | +3.56% | |
| Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -1.49% | +2.98% | |
| Form S-8 Opus Genetics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.82% | -1.84% | |
| Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference | Press release | GlobeNewswire | +0.15% | -1.18% | |
| Form 10-Q Opus Genetics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.15% | -1.18% | |
| Form 8-K Opus Genetics, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +2.98% | |
| Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update | Press release | GlobeNewswire | +1.19% | +2.98% | |
| Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study | Press release | GlobeNewswire | +0.19% | +1.90% | |
| Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases | Press release | GlobeNewswire | -1.27% | -6.73% | |
| Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program | Press release | GlobeNewswire | +0.85% | -2.07% | |
| Opus Genetics to Participate in Leading Medical Conferences in May 2026 | Press release | GlobeNewswire | +1.91% | -2.29% | |
| Form 8-K Opus Genetics, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | -2.29% | |
| Form EFFECT Opus Genetics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.37% | -4.23% | |
| Form 8-K Opus Genetics, Inc. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +3.60% | |
| Form S-3/A Opus Genetics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -1.02% | -2.91% | |
| Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting | Press release | GlobeNewswire | +1.46% | -2.54% | |
| Form 8-K Opus Genetics, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +5.35% | |
| Form 8-K Opus Genetics, Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.02% | |
| Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital | Press release | GlobeNewswire | +2.07% | +0.66% | |
| Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 | Press release | GlobeNewswire | +1.76% | -0.88% | |
| Form ARS Opus Genetics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.76% | -0.88% | |
| Form DEF 14A Opus Genetics, Inc. For: Apr 20 | SEC filing · Form DEF | SEC EDGAR | +1.76% | -0.88% | |
| Form S-3 Opus Genetics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.79% | +2.17% | |
| Form 10-K Opus Genetics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.31% | +2.65% | |
| Form PRE 14A Opus Genetics, Inc. For: Apr 20 | SEC filing · Form PRE | SEC EDGAR | -0.31% | +2.65% | |
| Form 8-K Opus Genetics, Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +1.36% | +1.68% | |
| Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | Press release | GlobeNewswire | +1.36% | +1.68% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IRD section they belong to.
Where else IRD is measured.
IRD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Opus Genetics, Inc.'s median reaction calculated?
Every labeled IRD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 183 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of IRD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IRD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.